Start here if you're new
what it is
Rallybio tries to develop drugs for rare diseases, mostly by betting on a tiny pipeline.
how it gets paid
Last year Rallybio made $600K in revenue. RLYB116 development revenue was the main engine at $240K, or 40% of sales.
what just happened
Rallybio posted $636K in revenue, while EPS stayed at -$0.07.
At a glance
C+ balance sheet — struggling to keep the lights on
-$10.64 fy2024 eps est
$1M fy2024 rev est
n/a operating margin
1.3 beta
xvary composite: 23/100 — weak
What they do
Rallybio tries to develop drugs for rare diseases, mostly by betting on a tiny pipeline.
RLYB116 is a differentiated C5 inhibitor, which means it blocks one immune signal. That is the closest thing Rallybio has to an edge. You are looking at 25 employees and $0M long-term debt, not a giant lab.
How they make money
$600K
annual revenue
RLYB116 development revenue
$240K
up
RLYB332 development revenue
$180K
up
RLYB212 wind-down revenue
$90K
dn
other collaboration revenue
$90K
flat
The products that matter
current business
Existing Rallybio business
$600K annual revenue
it's the full disclosed revenue base at $600K. that tells you the current company is not being valued on product sales.
today's reality
planned rare-disease T-cell platform
Candid merger assets
$505M transaction value
this is the real story. the planned $505M merger is more than 10x the current ~$50M market cap, which means financing and execution matter more than the legacy revenue line.
future thesis
listing survival signal
Reverse split
1-for-8 completed
a 1-for-8 reverse split does not create value. it buys listing compliance while reminding you how far the stock had already fallen.
capital markets tell
Key numbers
$50M
market cap
The whole company is priced like a small house, so one clinical miss can reprice the stock fast.
$0M
long-term debt
No long-term debt means less balance-sheet drama, which matters when the pipeline is tiny.
25
employees
A 25-person company has little room for mistakes, delays, or extra programs.
$600K
annual revenue
Revenue this small means the stock trades on drug data, not sales.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for RLYB right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Rallybio posted $636K in revenue, while EPS stayed at -$0.07.
Revenue was up 200% vs. prior year. The company still lost money because it is funding a 25-person pipeline.
$636K
revenue
-$0.07
eps
n/a
n/a
the number that mattered
The $636K quarter mattered because Rallybio still lives on clinical data, not sales.
source: EDGAR filing, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The main risk is specific and very visible: Rallybio is trying to bridge from a $600K revenue base and a ~$50M market cap into a planned $505M merger. That math usually asks existing shareholders for something.
med
merger financing and dilution
The planned transaction is valued at $505M against a current market cap of roughly $50M. That gap is the entire capital-markets problem. A company this small rarely funds a deal this large without asking current shareholders to absorb pain.
If financing shows up on punitive terms, the deal can close and the stock can still disappoint.
med
pipeline remains unproven
There are no commercial products supporting valuation today. Management is asking you to value future rare-disease T-cell programs before those assets have proven themselves inside this company.
No credible clinical proof means the stock keeps trading on hope, and hope is not a durable multiple.
med
cash burn versus flexibility
A -$10.64 fy2024 EPS estimate and a C+ balance sheet tell you losses are still doing the heavy lifting. Zero long-term debt helps, but it does not solve a small-biotech funding problem.
If losses persist without friendlier financing access, strategy gets dictated by liquidity instead of science.
med
listing and sentiment pressure
The 1-for-8 reverse split kept the stock listed, but that move usually tells you market trust was already damaged. Add a 5 / 100 price stability score and you get a stock that can gap on very little information.
Even neutral developments can hit a fragile shareholder base when volatility is this high.
If the $505M transaction gets delayed, repriced, or funded on rough terms, the whole thesis takes a hit because the current $600K revenue base does not give you much to fall back on.
source: institutional data · regulatory filings · risk analysis
Pay attention to
timeline
mid-2026 merger close
Management says the $505M Candid transaction is expected to close in mid-2026. If that slips, the market will start asking what changed and who pays for the delay.
financing
how much dilution it takes
A ~$50M company trying to absorb a $505M deal does not do it for free. Watch the financing terms more than the press-release optimism.
balance sheet
cash burn versus flexibility
C+ balance sheet grade, a -$10.64 EPS estimate, and zero debt mean equity is the obvious pressure valve. If the runway shortens, shareholders usually feel it first.
stock behavior
whether volatility calms down
A 1.3 beta and 5 / 100 price stability score tell you this trades like a special situation. If price action stays chaotic after financing clarity, the market is still signaling skepticism.
Analyst rankings
coverage quality
thin
There is not much analyst structure here to lean on. in human-speak, you should not confuse the existence of a small-cap biotech listing with the existence of a durable consensus.
earnings visibility
low
With no commercial product base and a merger-driven future, near-term estimates tell you more about cash burn than business momentum.
target usefulness
limited
When the core thesis depends on a mid-2026 transaction and later clinical proof, model precision is mostly theater.
source: institutional data
Institutional activity
institutional ownership data for RLYB is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive